Help CALM the CHAOS of UC
One pill, once a day
Discover VELSIPITY, the newest FDA-approved medicine of its class for adults with moderate to severe UC.
VELSIPITY was studied in a 52-week trial
There were 408 adult participants living with moderate to severe UC who had tried other medicines for UC that did not work well enough. Participants were selected at random to take either VELSIPITY or a placebo for the entirety of the trial. Participants may have received stable doses of oral 5-aminosalicylic acid derivatives and/or oral corticosteroids.
At 12 weeks, 27% of patients (n=75/274) achieved clinical remission* on VELSIPITY vs 7% (n=10/134) on placebo
- VELSIPITY
- Placebo
*Clinical remission was defined as stool frequency subscore of 0 (or 1 with a ≥1-point decrease from baseline), rectal bleeding subscore of 0, and endoscopy score ≤ 1 (excluding friability).
At 52 weeks, 32% of patients (n=89/274) achieved clinical remission* on VELSIPITY vs 7% on placebo (n=9/134).
- VELSIPITY
- Placebo
*Clinical remission was defined as stool frequency subscore of 0 (or 1 with a ≥1-point decrease from baseline), rectal bleeding subscore of 0, and endoscopy score ≤ 1 (excluding friability).
VELSIPITY was also studied in a 12-week trial
There were 333 adults living with moderate to severe UC who had tried other medicines for UC that did not work well enough. Participants were selected at random to take either VELSIPITY or a placebo for the entirety of the trial. Participants may have received stable doses of oral 5-aminosalicylic acid derivatives and/or oral corticosteroids.
At 12 weeks, 26% of patients (n=57/221) achieved clinical remission* on VELSIPITY vs 15% (n=17/112) on placebo.
- VELSIPITY
- Placebo
*Clinical remission was defined as stool frequency subscore of 0 (or 1 with a ≥1-point decrease from baseline), rectal bleeding subscore of 0, and endoscopy score ≤ 1 (excluding friability).
VELSIPITY works fast to treat flares. Some saw fewer bathroom trips in 2 weeks and less rectal bleeding in 4 weeks.
The safety of VELSIPITY was evaluated in 2 randomized, double-blind, placebo-controlled clinical trials.
Patients taking VELSIPITY may have an increased risk of infections and bradyarrhythmia (slow heart rate) in addition to other potential serious adverse events. See the Important Safety Information or Medication Guide for more information.
The most common side effects (≥5%) were headache, elevated liver tests, and dizziness. These are not all the possible side effects of VELSIPITY.
If you’re looking for another way to treat moderate to severe UC, talk to your doctor about VELSIPITY
If other treatments like 5-ASAs† or steroids aren’t working well enough* for you, ask your doctor about VELSIPITY.
†5-ASAs are 5-aminosalicylic acid derivatives.
*In VELSIPITY studies, people with moderately to severely active ulcerative colitis had an inadequate response, loss of response, or intolerance to one or more of the following treatment options: oral aminosalicylates, corticosteroids, thiopurines, Janus kinase (JAK) inhibitors, or biologics prior to enrollment.
Getting started with VELSIPITY
Before you start treatment with VELSIPITY, your doctor will request a few screening tests. You and your doctor will decide if these tests will happen in the doctor’s office or at your home for eligible, commercially insured patients.
Blood work
Complete blood count (CBC), including lymphocyte count and liver function tests.
ECG
An initial ECG (electrocardiogram) to rule out any pre-existing heart conditions you might not know about.
Eye & skin exams
Baseline exams to monitor any changes in your skin and eye health throughout your treatment.
It is also important to:
- Review vaccination records to ensure immunizations are up to date with current guidelines.
- Review list of current or prior medication, vitamins, and herbal supplements to discuss with your doctor prior to starting treatment.
Want to learn more about VELSIPITY?
Discover questions to ask your doctor and more information about VELSIPITY.
Download a printable guide to help you get started on VELSIPITY.
Pay as little as $0 per month for your VELSIPITY prescription†
As part of our Copay Savings Program, eligible† commercially insured patients may pay as little as $0 in out-of-pocket costs, with a maximum benefit of $16,000 per calendar year. See Terms and Conditions.
†Eligibility required. Commercially insured patients only. The maximum prescription benefit offer per patient is $16,000 per calendar year. Patients enrolled in a state or federally funded prescription health insurance program are not eligible. No membership fees. This is not health insurance. Available only to patients who have been diagnosed with an FDA-approved indication for VELSIPITY. Terms and Conditions apply.
Stay informed about VELSIPITY*
*Information provided through email subscription is only related to VELSIPITY, further information may be required for personalized financial support.
